Street View: Denali's first FDA nod signals regulatory flexibility for rare disease approvals

Denali Therapeutics

26/03/2026 11:47

** The U.S. Food and Drug Administration on Wednesday approved Denali Therapeutics' DNLI.O therapy to treat children with a rare genetic disorder, marking the first regulatory green light for the drugmaker in the country.

APPROVAL EASES INVESTOR CONCERNS

** William Blair ("outperform") says approval does suggest regulatory flexibility for rare disease, which could be a sector tailwind given FDA volatility and investor skepticism

**  TD Cowen ("buy") says the approval should come as welcome news following a three-month delay and uncertainty at the FDA; "likely a welcome relief for investors"

** Jefferies ("buy," PT: $40) says approval was generally expected despite the rejection for Regenxbio's gene therapy, RGX-121, for Hunter syndrome, says the decision is "still de-risking" for DNLI

** BTIG ("buy," PT: $38) says the approval gives DNLI a clear path to get complex drugs approved, which it can now leverage to fast-track the rest of its pipeline

** Evercore ISI ("outperform," PT: $31) says approval for co's treatment, Avlayah, was "widely-expected", says label supports a broader pediatric Hunter syndrome opportunity

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))